{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:44:12Z","timestamp":1786167852929,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07389-9","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:22:56Z","timestamp":1786166576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Racial and ethnic disparities in faricimab injections: a propensity matched cohort study"],"prefix":"10.1007","author":[{"given":"Abhimanyu S.","family":"Ahuja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Vasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella V.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syril K.","family":"Dorairaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin K.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"8","key":"7389_CR1","first-page":"1","volume":"2","author":"J Silvius","year":"2022","unstructured":"Silvius J, Bean S, Dunsky D et al (2022) Faricimab (Vabysmo): CADTH Reimbursement recommendation: indication: for the treatment of neovascular (Wet) Age-related macular degeneration. Can J Health Technol 2(8):1\u201315. https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2022\/SR0719REC-Vabysmo.pdf","journal-title":"Can J Health Technol"},{"issue":"7","key":"7389_CR2","first-page":"825","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M, Faricimab (2022) First Approval Drugs 82(7):825\u2013830","journal-title":"First Approval Drugs"},{"issue":"15","key":"7389_CR3","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.3390\/jcm13154508","volume":"13","author":"P Wolfrum","year":"2024","unstructured":"Wolfrum P, B\u00f6hm EW, Lorenz K et al (2024) Short-Term Clinical Outcomes of Patients with Diabetic Macular Edema Following a Therapy Switch to Faricimab. J Clin Med 13(15):4508","journal-title":"J Clin Med"},{"issue":"1","key":"7389_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.oret.2024.07.020","volume":"9","author":"SY Sim","year":"2025","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G et al (2025) Real-World 1-Year Outcomes of Treatment-Intensive Neovascular Age-Related Macular Degeneration Switched to Faricimab. Ophthalmol Retina 9(1):22\u201330","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"7389_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10384-024-01078-y","volume":"68","author":"M Shimura","year":"2024","unstructured":"Shimura M, Oh H, Ueda T et al (2024) YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial. Jpn J Ophthalmol 68(5):511\u2013522","journal-title":"Jpn J Ophthalmol"},{"issue":"16","key":"7389_CR6","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.3390\/ijms23169424","volume":"23","author":"S Liberski","year":"2022","unstructured":"Liberski S, Wichrowska M, Koci\u0119cki J (2022) Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Int J Mol Sci 23(16):9424","journal-title":"Int J Mol Sci"},{"issue":"7","key":"7389_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3928\/23258160-20220615-01","volume":"53","author":"TE Greenlee","year":"2022","unstructured":"Greenlee TE, Malhotra NA, Iyer AI et al (2022) Association of Socioeconomic Health Care Disparities With Use of Anti-Vascular Endothelial Growth Factor and Visual Acuity Outcomes in Patients With Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina 53(7):380\u2013391","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"7389_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"7","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 7(1):41\u201355","journal-title":"Biometrika"},{"issue":"2","key":"7389_CR9","first-page":"145","volume":"71","author":"PE Bath","year":"1979","unstructured":"Bath PE (1979) Rationale for a program in community ophthalmology. J Natl Med Assoc 71(2):145\u2013148","journal-title":"J Natl Med Assoc"},{"issue":"5","key":"7389_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3109\/09286586.2015.1066395","volume":"22","author":"DE Fisher","year":"2015","unstructured":"Fisher DE, Shrager S, Shea SJ et al (2015) Visual Impairment in White, Chinese, Black, and Hispanic Participants from the Multi-Ethnic Study of Atherosclerosis Cohort. Ophthalmic Epidemiol 22(5):321\u2013332","journal-title":"Ophthalmic Epidemiol"},{"key":"7389_CR11","doi-asserted-by":"crossref","unstructured":"Caraballo C, Massey D, Mahajan S et al (2020) Racial and Ethnic Disparities in Access to Health Care Among Adults in the United States: A 20-Year National Health Interview Survey Analysis, 1999\u20132018. medRxiv [Preprint]","DOI":"10.1101\/2020.10.30.20223420"},{"issue":"6","key":"7389_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.oret.2022.01.018","volume":"6","author":"T Bowe","year":"2022","unstructured":"Bowe T, Salabati M, Soares RR et al (2022) Racial, Ethnic, and Gender Disparities in Diabetic Macular Edema Clinical Trials. Ophthalmol Retina 6(6):531\u2013533","journal-title":"Ophthalmol Retina"},{"key":"7389_CR13","unstructured":"Joszt L (2022) FDA Approves Faricimab to Treat Wet AMD and DME. Am J Managed Care. https:\/\/www.ajmc.com\/view\/fda-approves-fariximab-to-treat-wet-amd-and-dme"},{"issue":"4","key":"7389_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","volume":"8","author":"SA Pandit","year":"2024","unstructured":"Pandit SA, Momenaei B, Wakabayashi T et al (2024) Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration. Ophthalmol Retina 8(4):360\u2013366","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"7389_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","volume":"8","author":"R Raimondi","year":"2024","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A et al (2024) Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab. Ophthalmol Retina 8(6):537\u2013544","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"7389_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/IAE.0b013e3181babd8e","volume":"30","author":"EW Gower","year":"2010","unstructured":"Gower EW, Cassard SD, Bass EB et al (2010) A cost-effectiveness analysis of three treatments for age-related macular degeneration. Retina 30(2):212\u2013221","journal-title":"Retina"},{"issue":"2","key":"7389_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ajo.2011.02.004","volume":"152","author":"BL Vanderbeek","year":"2011","unstructured":"Vanderbeek BL, Zacks DN, Talwar N et al (2011) Racial differences in age-related macular degeneration rates in the United States: a longitudinal analysis of a managed care network. Am J Ophthalmol 152(2):273\u2013282e3","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"7389_CR18","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","volume":"132","author":"R Varma","year":"2014","unstructured":"Varma R, Bressler NM, Doan QV et al (2014) Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 132(11):1334\u20131340","journal-title":"JAMA Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07389-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07389-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07389-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:22:58Z","timestamp":1786166578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07389-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":18,"alternative-id":["7389"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07389-9","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not meet the criteria for human subjects\u2019 research because it was an analysis of existing anonymized and aggregated data. TriNetX is a federated network and received a waiver from Western IRB because only aggregated counts and statistical summaries of de-identified data are reported. No protected health data were used and no study-specific activities were performed.","order":2,"name":"Ethics","label":"IRB statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"African American and Hispanic patients with neovascular age-related macular degeneration or macular edema were found to receive faricimab-svoa injections at significantly lower rates than their non-African American and non-Hispanic counterparts, highlighting potential racial and ethnic disparities in treatment utilization.","order":3,"name":"Ethics","label":"Summary statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}